India's DMPLOI - Jobs & Networking App
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) has announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for its proposed biosimilar to XOLAIR® (omalizumab), developed in partnership with Kashiv BioSciences, LLC. This strategic move positions Amneal for a potential first-wave entry into the lucrative $4+ billion U.S. omalizumab market, unlocking a significant new growth opportunity.
About Omalizumab
Omalizumab is a humanized monoclonal antibody that targets free IgE. It is indicated for the treatment of multiple conditions, including:
- Moderate to severe persistent asthma (patients 6 years and older)
- Chronic rhinosinusitis with nasal polyps (CRSwNP) (patients 18 years and older)
- Food allergies (patients over 1 year)
- Chronic spontaneous urticaria (patients 12 years and older)
The drug carries a black box warning for anaphylaxis, which may occur after the first dose or even after a year of treatment. Administration must be initiated and monitored in a healthcare setting, such as a hospital or clinic. Omalizumab is contraindicated in patients with severe hypersensitivity to the drug or any of its components.
Strategic Milestone for Amneal
“The earlier-than-expected BLA submission for this important therapeutic is excellent news for Amneal, as this product represents a significant potential growth catalyst in the coming years,” said Andy Boyer, Executive Vice President and Chief Commercial Officer, Affordable Medicines at Amneal Pharmaceuticals. “We are excited about the opportunity to be part of the first wave of omalizumab biosimilars in this large and attractive market.”
Amneal is rapidly expanding its biosimilars portfolio, with three products already on the market. The company expects five additional biosimilar launches between 2026 and 2027, including the omalizumab biosimilar, reinforcing its position as a strong competitor in the biosimilars space.
Kashiv’s Role and Biosimilar Expertise
“Kashiv continues to execute strongly on our expanding biosimilar portfolio, which already includes RELEUKO® (filgrastim-ayow) and FYLNETRA® (pegfilgrastim-pbbk). This BLA submission represents an important milestone in making our omalizumab biosimilar available to patients,” said Dr. Sandeep Athalye, Chief Executive Officer at Kashiv BioSciences.
Kashiv BioSciences has emerged as a U.S.-based leader in biosimilar development, with capabilities in manufacturing, regulatory affairs, and commercialization. Its partnership with Amneal reflects a shared commitment to high-quality, cost-effective biologic alternatives.
Market and Financial Impact
According to IQVIA®, U.S. annual sales for XOLAIR® totaled approximately $4.1 billion for the 12 months ending July 2025.
Due to the earlier BLA submission, Amneal expects to record a $22.5 million R&D milestone charge in the third quarter of 2025. This charge was already factored into the company’s financial guidance. Upon approval, Amneal will hold exclusive U.S. commercialization rights for the omalizumab biosimilar.
About Amneal Pharmaceuticals
Amneal Pharmaceuticals, Inc. is a global biopharmaceutical company headquartered in Bridgewater, New Jersey. With a diverse portfolio of over 280 products, Amneal focuses on affordable medicines, including generics, injectables, and biosimilars, as well as specialty pharmaceuticals targeting CNS and endocrine disorders. Its AvKARE segment distributes pharmaceutical products to U.S. federal, retail, and institutional markets.
About Kashiv BioSciences
Kashiv BioSciences, LLC is a vertically integrated biopharmaceutical company with strong global R&D, clinical, manufacturing, and regulatory capabilities. Operating in the U.S. and India, Kashiv focuses on advancing patient access to affordable, high-quality medicines through strategic collaborations and innovation.
